How do you choose your next line of therapy for stage 4 GIST after progression on imatinib?
How do you choose between local therapy (surgical debulking or ablation) v. 2nd line systemic therapy? Would you consider immunotherapy?
Answer from: Medical Oncologist at Academic Institution
At Sylvester we have found that patients with GIST whose tumors progress in imatinib often harbor resistance mutations that may be detected by a blood test called “circulating tumor DNA”. There is growing evidence that patients with one type of mutation do much better with sunitinib whil...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
This is an interesting and constantly evolving question. It is important to note that 80% of GIST have a mutation in KIT gene, with a further 10-12% having mutations in PDGFR gene. The remaining small fraction are referred to as wild type. It is important that note that wild-type GIST does not respo...
Comments
Medical Oncologist at Prostate Cancer Rsrch and Education Fndtn
I am writing a comment , because I am not sure how...
I am writing a comment , because I am not sure how...
Medical Oncologist at Dana-Farber Cancer Institute
I would only add that immunotherapy has shown limi...
I would only add that immunotherapy has shown limi...